RA Capital's Covid-19 Discussion 9

OCTOBER 7, 2020
Peter Kolchinsky, PhD, and members of the RA Capital Covid-19 Team
Discussion of the newly released data for Regeneron’s mAb cocktail and also on how the White House is dealing with a COVID-19 outbreak.

Sign up to access our Covid-19 discussions:

We offer periodic Zoom discussions with members of the RA Capital team on recent scientific developments related to Covid-19. We welcome participation from members of industry, government, media, academia, medicine, NGOs, and more. Please see our Covid-19 page for information regarding upcoming live discussions. All discussions are also recorded and posted to our library.

Please enter your email address to receive access to RA Capital's past and future Covid-19 discussions.

Our website handles your ongoing access to our Covid-19 Discussions via a browser cookie. If you delete your cookies or use a different browser, you will need to re-enter your email address to regain access. perspectives@racap.com if you should need technical assistance.

This system will not work with an old Internet Explorer browser. Chrome, Safari, and Internet Explorer 11 or later are all currently compatible.

Disclaimer:

RA Capital Management, LP (“RA Capital”) is an investment adviser registered with the Securities and Exchange Commission (“SEC”) under the Investment Advisers Act of 1940, as amended (“Advisers Act”).
From time to time, RA Capital may hold long and/or short positions in companies which are mentioned in this presentation. No remarks of any RA Capital personnel should be interpreted or construed as investment or other professional advice, and any discussion of individual companies is in no way inclusive of all the factors that should be considered when making an investment decision. Such considerations include, but are not limited to, the financial condition of a company, the skill of its management team, the evolving competitive landscape, and other revenue sources outside of the COVID-related projects which are the focus of today’s session. Therefore, nothing herein should be used to inform an investment decision. This discussion and the information presented in the discussion is for informational purposes only, and does not constitute a solicitation, recommendation, endorsement, offer or an inducement to invest with RA Capital or its funds, or to buy or sell any securities or other financial instruments in any jurisdiction. The factual information presented in this discussion is publicly available. The analysis of such information represents the views held by RA Capital and its employees as of the date of the presentation, and is subject to change without notification. Nothing in this presentation should be considered medical advice or guidance on the treatment or prevention of COVID.